Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells
暂无分享,去创建一个
[1] R. Larsson,et al. Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. , 1994, Anti-cancer drugs.
[2] J. Sacher,et al. Mutual amplification of apoptosis by statin‐induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells , 2004, British journal of pharmacology.
[3] Susan Budavari,et al. The Merck index : an encyclopedia of chemicals, drugs, and biologicals , 1983 .
[4] C. Cleeland,et al. The role of statins in cancer therapy. , 2006, The oncologist.
[5] N. Gronich,et al. Simvastatin Induces Death of Multiple Myeloma Cell Lines , 2004, Journal of Investigative Medicine.
[6] H. Murota,et al. Effects of a 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor and low‐density lipoprotein on proliferation and migration of keratinocytes , 2010, The British journal of dermatology.
[7] S. Cohen,et al. Cellular effects of hypercholesterolemia in modulation of cancer growth and metastasis: a review of the evidence. , 1997, Surgical oncology.
[8] T. Stokłosa,et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] J. Gołąb,et al. Potential antitumor effects of statins (Review). , 2003, International journal of oncology.
[10] Z. Darżynkiewicz,et al. Cell cycle-specific effects of lovastatin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[11] H. Rogers,et al. A Textbook of Clinical Pharmacology , 1981 .
[12] M. Lishner,et al. Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines , 2004, Anti-cancer drugs.
[13] F. Denizot,et al. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.
[14] A. Józkowicz,et al. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. , 2005, Current cancer drug targets.
[15] P. Singal,et al. Lipid lowering: an important factor in preventing adriamycin-induced heart failure. , 1997, The American journal of pathology.
[16] S. Sleijfer,et al. The potential of statins as part of anti-cancer treatment. , 2005, European journal of cancer.
[17] G. Meinhardt,et al. Synergistic antimyeloma effects of zoledronate and simvastatin , 2006, Anti-cancer drugs.
[18] Kelvin K. W. Chan,et al. The statins as anticancer agents. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.